gefitinib has been researched along with Carcinoma, Large Cell in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 19 (55.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, SZ; Du, L; Shi, ZL; Wang, Z; Xu, YJ; Zhang, X | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Avila Martínez, RJ; Hernández Voth, A; Villena Garrido, V | 1 |
| Costanzo, R; De Lutio, E; Franco, R; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rachiglio, AM; Rocco, G; Sandomenico, C | 1 |
| Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Karaseva, NA; Kulikova, YE; Lozhkina, AM; Mitiushkina, NV; Orlov, SV; Tiurin, VI; Togo, AV; Volodina, LN | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H | 1 |
| Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Barberis, M; Catania, C; De Pas, TM; Giovannini, M; Labianca, R; Manzotti, M; Spaggiari, L; Toffalorio, F; Trifirò, G | 1 |
| Brown, MP; Cheetham, G; Scott, HS; Sharma, A; Tan, TH | 1 |
| Goya, T; Koshiishi, Y; Miya, T; Ono, Y; Tanaka, H | 1 |
| Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A | 1 |
| Abe, S; Chiba, H; Hasegawa, T; Igarashi, Y; Inokuchi, J; Iseki, K; Ishii, A; Kabayama, K; Kaneko, M; Noguchi, M; Saitoh, M; Satoh, M; Shiratori, M; Suzuki, T; Tagami, S; Takahashi, H; Watanabe, A | 1 |
| Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
1 review(s) available for gefitinib and Carcinoma, Large Cell
| Article | Year |
|---|---|
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
6 trial(s) available for gefitinib and Carcinoma, Large Cell
| Article | Year |
|---|---|
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2006 |
Clinical experience with gefitinib in Indian patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
27 other study(ies) available for gefitinib and Carcinoma, Large Cell
| Article | Year |
|---|---|
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Large Cell; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged | 2018 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Spontaneous hemothorax as a presenting form of bronchogenic carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Large Cell; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Hemothorax; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Pulmonary Atelectasis; Quinazolines; Rupture, Spontaneous; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2013 |
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Topics: Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Large Cell; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines | 2008 |
A population-based study of gefitinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
[Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Large Cell; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Radiation Pneumonitis | 2003 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; G(M3) Ganglioside; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Sialyltransferases; Tumor Cells, Cultured | 2007 |